These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19246367)

  • 1. Acute promyelocytic leukemia--weapons of mass differentiation.
    Licht JD
    N Engl J Med; 2009 Feb; 360(9):928-30. PubMed ID: 19246367
    [No Abstract]   [Full Text] [Related]  

  • 2. Retinoic acid and arsenic for treating acute promyelocytic leukemia.
    Zhou GB; Zhao WL; Wang ZY; Chen SJ; Chen Z
    PLoS Med; 2005 Jan; 2(1):e12. PubMed ID: 15696202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-simulating agents selectively stimulate arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
    Tamm I
    Haematologica; 2005 Dec; 90(12):1585A. PubMed ID: 16330421
    [No Abstract]   [Full Text] [Related]  

  • 4. Curing APL: differentiation or destruction?
    Kogan SC
    Cancer Cell; 2009 Jan; 15(1):7-8. PubMed ID: 19111876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
    Nasr R; de Thé H
    Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hot on the TRAIL of acute promyelocytic leukemia.
    Zelent A
    Nat Med; 2001 Jun; 7(6):662-4. PubMed ID: 11385499
    [No Abstract]   [Full Text] [Related]  

  • 7. All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).
    Orfali N; O'Donovan TR; Cahill MR; Benjamin D; Nanus DM; McKenna SL; Gudas LJ; Mongan NP
    Eur J Haematol; 2020 Mar; 104(3):236-250. PubMed ID: 31811682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
    Vitoux D; Nasr R; de The H
    Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia.
    Lo Coco F; Diverio D; Falini B; Biondi A; Nervi C; Pelicci PG
    Blood; 1999 Jul; 94(1):12-22. PubMed ID: 10381493
    [No Abstract]   [Full Text] [Related]  

  • 10. The maturation of differentiation therapy.
    Cheson BD
    N Engl J Med; 1992 Aug; 327(6):422-4. PubMed ID: 1625719
    [No Abstract]   [Full Text] [Related]  

  • 11. [Role of retinoic acid in the treatment of acute promyelocytic leukemia].
    Gutiérrez de Guzmán J; Kantarjian H
    Sangre (Barc); 1993 Oct; 38(5):375-8. PubMed ID: 8140499
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D; Mistry AR; Solomon E; Guidez F
    Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid.
    Mazharuddin S; Chattopadhyay A; Levy MY; Redner RL
    Leuk Lymphoma; 2018 Sep; 59(9):2246-2249. PubMed ID: 29350080
    [No Abstract]   [Full Text] [Related]  

  • 14. APL, a model disease for cancer therapies?
    de Thé H; Chelbi-Alix MK
    Oncogene; 2001 Oct; 20(49):7136-9. PubMed ID: 11704841
    [No Abstract]   [Full Text] [Related]  

  • 15. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy.
    Ding W; Li YP; Nobile LM; Grills G; Carrera I; Paietta E; Tallman MS; Wiernik PH; Gallagher RE
    Blood; 1998 Aug; 92(4):1172-83. PubMed ID: 9694705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathogenesis of acute promyelocytic leukemia].
    Tokuhira M; Kizaki M
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():409-14. PubMed ID: 23133991
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of a novel PML-RARG fusion in acute promyelocytic leukemia.
    Ha JS; Do YR; Ki CS; Lee C; Kim DH; Lee W; Ryoo NH; Jeon DS
    Leukemia; 2017 Sep; 31(9):1992-1995. PubMed ID: 28555082
    [No Abstract]   [Full Text] [Related]  

  • 18. Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.
    Leiva M; Moretti S; Soilihi H; Pallavicini I; Peres L; Mercurio C; Dal Zuffo R; Minucci S; de Thé H
    Leukemia; 2012 Jul; 26(7):1630-7. PubMed ID: 22333881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia.
    Wang ZY; Chen Z
    Lancet Oncol; 2000 Oct; 1():101-6. PubMed ID: 11905660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
    Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
    Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.